Skip to content
Medical Health Aged Care

Scanfil Strengthens its Customer Portfolio in Medtech & Life Science by Signing Agreement with Liquid Instruments

Scanfil 2 mins read
MELBOURNE, Australia--BUSINESS WIRE--

Scanfil and Liquid Instruments have signed a manufacturing outsourcing agreement for Scanfil’s Melbourne plant in Australia. This agreement supports Liquid Instruments’ strategy to onshore production of its flagship Moku platform, strengthening domestic supply chains and bringing manufacturing closer to its research and development hub.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250625717512/en/

This agreement supports Liquid Instruments’ strategy to onshore production of its flagship Moku platform, strengthening domestic supply chains and bringing manufacturing closer to its research and development hub. Photo by Scanfil.

This agreement supports Liquid Instruments’ strategy to onshore production of its flagship Moku platform, strengthening domestic supply chains and bringing manufacturing closer to its research and development hub. Photo by Scanfil.

“We’re continuing to expand our manufacturing footprint in Australia,” says Daniel Shaddock, CEO of Liquid Instruments. “Onshoring production through this partnership allows us to scale more efficiently, while deepening our investment in Australia’s technology ecosystem. Scanfil’s expertise and strong local presence make them the ideal partner for this next phase of growth.”

The collaboration will leverage Scanfil's and its subsidiary, SRXGlobal's, expertise in Medtech & Life Science. Liquid Instruments will benefit from supply chain management, scalable manufacturing, global delivery capabilities, and aftermarket services — all in Victoria, Australia.

"Liquid Instruments has developed a unique product with an interesting and complex technology that is a perfect fit for the services provided by SRXGlobal in Australia. We at Scanfil and SRXGlobal are thrilled and excited that Liquid Instruments has chosen SRXGlobal as their preferred manufacturing partner for the exciting journey ahead, and we look forward to a strong and successful partnership", states Christian Kesten, VP of Scanfil APAC.

Scanfil in brief

Scanfil plc is Europe’s largest listed provider of electronics manufacturing services (EMS), whose turnover in 2024 amounted to EUR 780 million. The company serves global sector leaders in the customer segments of Industrial, Energy & Cleantech, and Medtech & Life Science. The company’s services include design services, prototype manufacture, design for manufacturability (DFM) services, test development, supply chain and logistics services, circuit board assembly, manufacture of subsystems and components, and complex systems integration services. Scanfil’s objective is to grow customer value by improving their competitiveness and by being their primary supply chain partner and long-term manufacturing partner internationally. Scanfil’s longest-standing customer account has continued for more than 40 years. The company has global supply capabilities and eleven production facilities across four continents. www.scanfil.com


Contact details:

Further information:
Christian Kesten
Vice President, APAC region
tel. +86 512 67168867 6101
[email protected]

Pasi Hiedanpää
Director, Investor Relations and Communications
tel. +358 50 378 2228
[email protected]

Media

More from this category

  • General News, Medical Health Aged Care
  • 12/03/2026
  • 14:07
Parliament of Australia

Public hearing concerning the National Redress Scheme

TheJoint Standing Committee on Implementation of the National Redress Schemewill hold a public hearing in Canberra on Friday, 13 March 2026, for itsinquiry into the continuing operation of the Scheme. Committee Chair, Ms Jodie Belyea MP, said the Committee is grateful for the contributions made in support of the inquiry to date. ‘The National Redress Scheme plays a central role in Australia’s response to institutional child sexual abuse. It is an important program for a significant number of people. The Committee has received a substantial number of submissions in support of our current inquiry, and public hearings over the coming…

  • Energy, Medical Health Aged Care
  • 12/03/2026
  • 12:11
Sweltering Cities

The cost of keeping cool is making Australians sick: New report reveals millions forced to ration cooling during record heat

12 March 2026 Sweltering Cities has today released the findings of its 2026 Summer Survey, exposing a national health crisis driven by the rising cost of keeping cool. With data from more than 2,600 respondents across 766 postcodes, the report proves that for many Australians the high cost of staying cool is having serious physical and mental health impacts. The 2025/26 summer saw 68% of all respondents report feeling unwell due to heat. However, the survey reveals that this burden is falling most heavily on those already struggling with the cost of living. For renters and people with disabilities, the…

  • Medical Health Aged Care
  • 12/03/2026
  • 10:01
Monash University

Monash Researchers Awarded up to $22.4 Million AUD to Develop New Medicines for Restoring Lymphatic Pumping

Monash University is partnering with the University of Missouri and the University of Pennsylvania to develop first-in-class medicines designed to reverse poor lymphatic vessel contraction and transport function, backed by an up to $22.4 million AUD Award from the Advanced Research Projects Agency for Health (ARPA-H). The researchers join ARPA-H’s GLIDE (Groundbreaking Lymphatic Interventions and Drug Exploration) program to transform how both primary lymphatic diseases and common chronic diseases are treated by developing innovative therapeutics that alleviate, repair or regenerate a dysfunctional lymphatic vascular system. Professor Arthur Christopoulos, Dean of the Faculty of Pharmacy and Pharmaceutical Sciences, said the work…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.